BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11400244)

  • 1. Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience.
    Colnot DR; Quak JJ; Roos JC; de Bree R; Wilhelm AJ; Snow GB; van Dongen GA
    Head Neck; 2001 Jul; 23(7):559-65. PubMed ID: 11400244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
    J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy.
    Colnot DR; Wilhelm AJ; Cloos J; Roos JC; de Bree R; Quak JJ; Snow GB; van Dongen GA
    J Nucl Med; 2001 Sep; 42(9):1364-7. PubMed ID: 11535726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
    Colnot DR; Ossenkoppele GJ; Roos JC; Quak JJ; de Bree R; Börjesson PK; Huijgens PC; Snow GB; van Dongen GA
    Clin Cancer Res; 2002 Nov; 8(11):3401-6. PubMed ID: 12429627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
    Gerretsen M; Visser GW; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Cancer Res; 1993 Aug; 53(15):3524-9. PubMed ID: 8339258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
    van Gog FB; Visser GW; Stroomer JW; Roos JC; Snow GB; van Dongen GA
    Cancer; 1997 Dec; 80(12 Suppl):2360-70. PubMed ID: 9406684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.
    de Bree R; Roos JC; Plaizier MA; Quak JJ; van Kamp GJ; den Hollander W; Snow GB; van Dongen GA
    Br J Cancer; 1997; 75(7):1049-60. PubMed ID: 9083342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
    Breitz HB; Weiden PL; Vanderheyden JL; Appelbaum JW; Bjorn MJ; Fer MF; Wolf SB; Ratliff BA; Seiler CA; Foisie DC
    J Nucl Med; 1992 Jun; 33(6):1099-109. PubMed ID: 1597723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
    Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
    Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How far have we come with solid (nonhematologic) tumor radioimmunotherapy?
    Breitz HB
    J Nucl Med; 2000 Dec; 41(12):2011-4. PubMed ID: 11138686
    [No Abstract]   [Full Text] [Related]  

  • 13. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer.
    van Gog FB; Brakenhoff RH; Stigter-van Walsum M; Snow GB; van Dongen GA
    Int J Cancer; 1998 Jul; 77(1):13-8. PubMed ID: 9639387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
    J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete ablation of small squamous cell carcinoma xenografts with 186Re-labeled monoclonal antibody E48.
    Gerretsen M; Visser GW; Brakenhoff RH; van Walsum M; Snow GB; van Dongen GA
    Cell Biophys; 1994; 24-25():135-42. PubMed ID: 7736517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol.
    Visser GW; Gerretsen M; Herscheid JD; Snow GB; van Dongen G
    J Nucl Med; 1993 Nov; 34(11):1953-63. PubMed ID: 8229241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
    de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
    Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
    van Gog FB; Visser GW; Klok R; van der Schors R; Snow GB; van Dongen GA
    J Nucl Med; 1996 Feb; 37(2):352-62. PubMed ID: 8667076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
    Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.